Mast cell proteases as pharmacological targets
- PMID: 25958181
- PMCID: PMC4636979
- DOI: 10.1016/j.ejphar.2015.04.045
Mast cell proteases as pharmacological targets
Abstract
Mast cells are rich in proteases, which are the major proteins of intracellular granules and are released with histamine and heparin by activated cells. Most of these proteases are active in the granule as well as outside of the mast cell when secreted, and can cleave targets near degranulating mast cells and in adjoining tissue compartments. Some proteases released from mast cells reach the bloodstream and may have far-reaching actions. In terms of relative amounts, the major mast cell proteases include the tryptases, chymases, cathepsin G, carboxypeptidase A3, dipeptidylpeptidase I/cathepsin C, and cathepsins L and S. Some mast cells also produce granzyme B, plasminogen activators, and matrix metalloproteinases. Tryptases and chymases are almost entirely mast cell-specific, whereas other proteases, such as cathepsins G, C, and L are expressed by a variety of inflammatory cells. Carboxypeptidase A3 expression is a property shared by basophils and mast cells. Other proteases, such as mastins, are largely basophil-specific, although human basophils are protease-deficient compared with their murine counterparts. The major classes of mast cell proteases have been targeted for development of therapeutic inhibitors. Also, a human β-tryptase has been proposed as a potential drug itself, to inactivate of snake venins. Diseases linked to mast cell proteases include allergic diseases, such as asthma, eczema, and anaphylaxis, but also include non-allergic diseases such as inflammatory bowel disease, autoimmune arthritis, atherosclerosis, aortic aneurysms, hypertension, myocardial infarction, heart failure, pulmonary hypertension and scarring diseases of lungs and other organs. In some cases, studies performed in mouse models suggest protective or homeostatic roles for specific proteases (or groups of proteases) in infections by bacteria, worms and other parasites, and even in allergic inflammation. At the same time, a clearer picture has emerged of differences in the properties and patterns of expression of proteases expressed in human mast cell subsets, and in humans versus other mammals. These considerations are influencing prioritization of specific protease targets for therapeutic inhibition, as well as options of pre-clinical models, disease indications, and choice of topical versus systemic routes of inhibitor administration.
Keywords: Basophil; Carboxypeptidase A3; Cathepsin C; Cathepsin G; Cathepsin L; Chymase; Dipeptidylpeptidase I; Mast cell; Protease; Tryptase.
Published by Elsevier B.V.
Similar articles
-
Mast Cell and Basophil Granule Proteases - In Vivo Targets and Function.Front Immunol. 2022 Jul 5;13:918305. doi: 10.3389/fimmu.2022.918305. eCollection 2022. Front Immunol. 2022. PMID: 35865537 Free PMC article. Review.
-
Mast cell proteases as protective and inflammatory mediators.Adv Exp Med Biol. 2011;716:212-34. doi: 10.1007/978-1-4419-9533-9_12. Adv Exp Med Biol. 2011. PMID: 21713659 Free PMC article. Review.
-
Human mast cells arise from a common circulating progenitor.J Allergy Clin Immunol. 2013 Aug;132(2):463-9.e3. doi: 10.1016/j.jaci.2013.02.011. Epub 2013 Apr 9. J Allergy Clin Immunol. 2013. PMID: 23582567
-
Update on Mast Cell Proteases as Drug Targets.Immunol Allergy Clin North Am. 2023 Nov;43(4):777-787. doi: 10.1016/j.iac.2023.04.006. Epub 2023 May 21. Immunol Allergy Clin North Am. 2023. PMID: 37758413 Review.
-
Mast cell cathepsins C and S control levels of carboxypeptidase A and the chymase, mouse mast cell protease 5.Biol Chem. 2003 Oct-Nov;384(10-11):1527-31. doi: 10.1515/BC.2003.169. Biol Chem. 2003. PMID: 14669996
Cited by
-
Inflammatory Serine Proteases Play a Critical Role in the Early Pathogenesis of Diabetic Cardiomyopathy.Cell Physiol Biochem. 2019;53(6):982-998. doi: 10.33594/000000190. Cell Physiol Biochem. 2019. PMID: 31829530 Free PMC article.
-
Mast Cell and Basophil Granule Proteases - In Vivo Targets and Function.Front Immunol. 2022 Jul 5;13:918305. doi: 10.3389/fimmu.2022.918305. eCollection 2022. Front Immunol. 2022. PMID: 35865537 Free PMC article. Review.
-
Phenotypic and Functional Diversity of Mast Cells.Int J Mol Sci. 2020 May 28;21(11):3835. doi: 10.3390/ijms21113835. Int J Mol Sci. 2020. PMID: 32481605 Free PMC article.
-
Protease Inhibitors in Tick Saliva: The Role of Serpins and Cystatins in Tick-host-Pathogen Interaction.Front Cell Infect Microbiol. 2017 May 29;7:216. doi: 10.3389/fcimb.2017.00216. eCollection 2017. Front Cell Infect Microbiol. 2017. PMID: 28611951 Free PMC article. Review.
-
Medicinal leech therapy-an overall perspective.Integr Med Res. 2017 Dec;6(4):337-343. doi: 10.1016/j.imr.2017.08.001. Epub 2017 Aug 10. Integr Med Res. 2017. PMID: 29296560 Free PMC article. Review.
References
-
- Abonia JP, Friend DS, Austen WG, Jr, Moore FD, Jr, Carroll MC, Chan R, Afnan J, Humbles A, Gerard C, Knight P, Kanaoka Y, Yasuda S, Morokawa N, Austen KF, Stevens RL, Gurish MF. Mast cell protease 5 mediates ischemia-reperfusion injury of mouse skeletal muscle. J Immunol. 2005;174:7285–7291. - PMC - PubMed
-
- Akahoshi M, Song CH, Piliponsky AM, Metz M, Guzzetta A, Abrink M, Schlenner SM, Feyerabend TB, Rodewald HR, Pejler G, Tsai M, Galli SJ. Mast cell chymase reduces the toxicity of Gila monster venom, scorpion venom, and vasoactive intestinal polypeptide in mice. J Clin Invest. 2011;121:4180–4191. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources